Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.
OBJECTIVE
To examine the effect of treatment with an inactivated, gp120-depleted, HIV-1 immunogen (Remune) in 30 Thai subjects infected with HIV-1 subtype E.


METHODS
Sixty-week open-label study.


METHODS
Thirty HIV-positive volunteers with CD4 cell counts > or = 300 x 10(6)/l were given intramuscular injections of Remune into the triceps muscle on day 1 and then at weeks 4, 8, 12, 24, 36, 48 and 60.


RESULTS
Treatment with Remune was well-tolerated and augmented HIV-1-specific immune responses. Furthermore, subjects had a significant increase in CD4 cell count (P < 0.0001), CD4 cell percentage (P < 0.0001), CD8 cell percentage (P < 0.0001), and body weight (P < 0.0001) compared with pretreatment levels. Fourteen subjects with detectable viral load at day 1 showed a decrease at week 60 (P=0.04). Retrospective Western blot analysis showed 23 subjects with increased intensity of antibody bands and 15 patients showed development of new reactivities to HIV proteins, especially towards p17 and p15.


CONCLUSIONS
These results indicate that HIV-specific immune-based therapeutic approaches such as Remune should be further examined in countries with different clades of HIV-1 and where access to antiviral drug therapies is limited.
Churdboonchart
V
V
Mahidol University, Phayathai, Bangkok, Thailand.
Moss
R B
RB
Sirawaraporn
W
W
Smutharaks
B
B
Sutthent
R
R
Jensen
F C
FC
Vacharak
P
P
Grimes
J
J
Theofan
G
G
Carlo
D J
DJ
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D015153:Blotting, Western; D018791:CD4 Lymphocyte Count; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000628:therapy* / Q000821:virology; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D016233:Immunotherapy, Active; D008297:Male; D012367:RNA, Viral / Q000097:blood; D013785:Thailand; D013997:Time Factors; D016896:Treatment Outcome; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000627:therapeutic use*; D019562:Viral Load
D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D012367:RNA, Viral; D015164:Vaccines, Inactivated